Liquidity is under severe pressure as evidenced by the OCF/NI ratio dropping to 0.09 in 2025Q4, reflecting a persistent reliance on external financing to cover deep negative free cash flows.
| Cash from Operations | -106.6M | -102.67M | -82.44M | -84.12M | -104.47M | -63.25M | -20.77M | -7.85M |
| Operating CF Margin % | - | -2511.01% | -26765.26% | -26789.17% | -44835.62% | -310.39% | - | - |
| Operating CF Growth % | -124.36% | -24.55% | 2% | 19.48% | -65.18% | -204.57% | -164.67% | - |
| Net Income | -663.4M | -660.05M | -150.05M | -43.9M | -157.42M | -174.24M | -178.63M | -24.38M |
| Depreciation & Amortization | 627K | 1.01M | 473K | 319K | 168K | 47K | 24K | 6K |
| Stock-Based Compensation | 11.43M | 0 | 25.49M | 32.98M | 42.38M | 63.36M | 67.16M | 57K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 5.07M | 39.13M | 56.35M | 7.54M |
| Other Non-Cash Items | 547.96M | 562.84M | 50.85M | -80.99M | 8.67M | 16.06M | 29.88M | 9.06M |
| Working Capital Changes | -3.15M | -6.47M | -9.2M | 7.47M | -3.33M | -7.6M | 4.45M | -126K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 4.05M | -1.7M | -1.87M | 2.14M | -3.03M | 2.3M | 1.7M | 249K |
| Cash from Investing | -120.02M | -109.13M | 59.17M | -53.3M | -86.85M | -81.28M | -28.27M | -9.03M |
| Capital Expenditures | -10.9M | -10.87M | -95K | -259K | -773K | -1.13M | -59K | -19K |
| CapEx % of Revenue | 312.61% | 265.79% | 30.84% | 82.48% | 331.76% | 5.54% | - | - |
| Acquisitions | 5.67M | 4.64M | 359K | -443K | 0 | -52.94M | -2.09M | -456K |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | -17.91M | -13M | -8.1M | -5.84M | -3.25M | -2.6M | -2.2M | -7.32M |
| Cash from Financing | 213.28M | 269.48M | 5.37M | -8.36M | 20.79M | 409.86M | 113.05M | 40.39M |
| Debt Issued (Net) | 29.76M | 7.71M | 5M | 0 | 15M | 1.59M | 32.5M | 0 |
| Equity Issued (Net) | 198.23M | 283.43M | 535K | 0 | 600K | 405.86M | 82.44M | 42.68M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -3.56M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -14.71M | -21.66M | -161K | -8.36M | 5.18M | 2.42M | -1.89M | -2.29M |
| Net Change in Cash | -15.19M | 57.8M | -17.53M | -145.58M | -171.65M | 265.02M | 67.18M | 23.14M |
| Free Cash Flow | -117.19M | -103.58M | -82.53M | -84.71M | -105.49M | -64.37M | -20.82M | -7.87M |
| FCF Margin % | -3359.77% | -2533.04% | -26796.1% | -26977.07% | -45275.11% | -315.93% | - | - |
| FCF Growth % | -50.42% | -25.5% | 2.57% | 19.7% | -63.87% | -209.12% | -164.78% | - |
| FCF per Share | -0.52 | -0.46 | -0.52 | -0.53 | -0.68 | -0.40 | -0.14 | -0.05 |
| FCF Conversion (FCF/Net Income) | 0.18x | 0.16x | 0.55x | 2.09x | 0.69x | 0.38x | 0.12x | 0.55x |
| Interest Paid | 203K | 0 | 2.16M | 1.92M | 0 | 0 | 0 | 0 |
| Taxes Paid | 55K | 0 | 411K | 1.48M | 0 | 0 | 0 | 0 |
Clinical Trial Funding Runway
As reported in recent financial statements, ATAI's operating cash flow consistently trails net income, with the OCF/NI ratio fluctuating significantly, reaching a low of 0.09 in 2025Q4, which highlights the disconnect between accounting losses and the actual cash required to sustain clinical operations.
The wide variance in the OCF/NI ratio suggests that net income is a poor proxy for the company's actual cash requirements. Investors should monitor this divergence, as it indicates that non-cash charges and accounting adjustments frequently obscure the underlying cash burn rate inherent in the firm's R&D-heavy business model.
Based on quarterly cash flow data, ATAI's free cash flow remains deeply negative, with quarterly outflows frequently exceeding $20 million, a trend that underscores the company's reliance on external financing to fund its extensive pipeline of psychedelic-focused clinical trials and decentralized research infrastructure.
The consistent negative FCF trajectory suggests that the company is far from achieving self-sustaining operations. Without a clear path to commercialization, the current cash burn appears to be a structural feature of the business rather than a temporary phase, warranting caution regarding future liquidity.
According to historical filings, ATAI's capital expenditure patterns are erratic, with a notable $10.4 million outflow in 2025Q4, suggesting that the firm's investment in physical or intangible assets is driven by specific project milestones rather than a predictable, recurring maintenance or growth cycle.
The lack of consistent capital investment suggests that the company is prioritizing immediate clinical trial costs over long-term infrastructure development. This approach may indicate a strategy focused on rapid asset iteration, but it also leaves the firm vulnerable to sudden spikes in capital requirements as programs advance.
Data from recent quarterly reports indicates that working capital changes are highly volatile, swinging from a $7.8 million inflow in 2025Q2 to an $11.7 million outflow in 2025Q4, which complicates the predictability of the company's short-term cash position and overall liquidity management.
These fluctuations in working capital appear to be driven by the timing of milestone payments and clinical trial vendor obligations. Investors should monitor these shifts closely, as they may indicate underlying challenges in managing cash cycles within a decentralized, multi-subsidiary corporate structure.
As indicated by the provided cash flow data, stock-based compensation has reached as high as $8.4 million in a single quarter, which effectively masks the true economic cost of talent acquisition and retention in the highly competitive psychedelic pharmaceutical research sector.
By relying heavily on equity-based incentives, the company preserves cash in the short term but creates a significant dilution risk for existing shareholders. This practice warrants further investigation into whether the current compensation structure aligns management incentives with long-term clinical success or merely short-term survival.
Quick answers to the most common questions about buying ATAI stock.
Atai Beckley N.V (ATAI) generated $-102.7M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Atai Beckley N.V (ATAI) reported negative free cash flow of $103.6M in 2025, indicating capital requirements exceeded cash from operations.
Atai Beckley N.V (ATAI) spent $10.9M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.